Xylometazoline

ApprovedSmall molecule

Novartis

Xylometazoline is one of 155 small molecule programs targeting Common Cold. It is currently in Approved.

Indications

Total Trials

Active Trials

154

Competitors

Pipeline

Status by Indication[3][1]

Indication

Common ColdActive, not recruiting

SinusitisActive, not recruiting

Obstructive Sleep ApneaActive, not recruiting

Otitis MediaActive, not recruiting

Sleep ApneaActive, not recruiting

Common ColdPhase 3

Active, not recruiting

SinusitisPreclinical

Active, not recruiting

Obstructive Sleep ApneaApproved

Active, not recruiting

Otitis MediaPreclinical

Active, not recruiting

Sleep ApneaPreclinical

Active, not recruiting

Competition

Competitive Landscape

149 competitors in Obstructive Sleep Apnea

#DrugCompanyPhaseTrials

Foundayo

Eli Lilly

Phase 3

1 2

Mounjaro

Eli Lilly

Phase 3

1 3

Farxiga

AstraZeneca

Phase 3

1 4

Asmanex

Novartis

Phase 3

1 5

Xylometazoline

Novartis

Approved

1 6

MS Contin

Lunesta

3 8

MS Contin

HHikma Pharmaceuticals LLC

Phase 3

2 9

Ketalar

AAultman Health Foundation

Phase 3

2 10

Imovane

TTaisho Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sinusitis2 trials

Non-interventional Study With Ectoin Containing and/or Decongesting Nasal Spray in Patients With Rhinosinusitis

Completed·BBitop AG··NCT03693976·168 enrolled

Non-interventional Study of Ectoin Nasal Douche (END01) in Patients With Acute Viral Rhinosinusitis

Completed·BBitop AG··NCT03480100·120 enrolled

Bronchoscopy1 trial

Xylometazoline During Nasal Flexible Bronchoscopy

Completed·—·N/A·NCT03424889·148 enrolled

Obstructive Sleep Apnea1 trial

Nasal Decongestion and Obstructive Sleep Apnea

Completed·UUniversity of Zurich·Phase 4·NCT00630474·12 enrolled

Sleep Apnea1 trial

The Role of the Nose in Snoring and Sleep Apnea

Unknown status·—·N/A·NCT03072173·30 enrolled

Common Cold1 trial

Decongestant Effect, Timing of Effect and Impact on Sleep and General Well-Being of Xylometazoline in Subjects With a Common Cold

Completed· Novartis logo

Novartis·Phase 3·NCT00452270·60 enrolled

1 more indication

Otitis media1 trial

LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media

Completed·AAnabio R&D·N/A·NCT05804123·175 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Xylometazoline. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Xylometazoline compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Xylometazoline. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

Xylometazoline

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Sinusitis2 trials

Bronchoscopy1 trial

Obstructive Sleep Apnea1 trial

Sleep Apnea1 trial

Common Cold1 trial

Otitis media1 trial

References

Drug Info

Quick Facts

Related News